One Percent Rule Checklist For Safer Forex Trading Risk 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
GAITHERSBURG, Md., April 20, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 4, 2017 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2017, recent business developments, revenue guidance for the second quarter of 2017, and revenue and net income guidance for full year 2017.
This conference call can be accessed live by telephone or via webcast:
| Live Teleconference Information: Dial in number: (855) 766-6521 International dial in: (262) 912-6157 Conference ID: 29691796 |
| Live Webcast Information: |
| Visit http://edge.media-server.com/m/p/523ryq7t for the live webcast feed. |
A replay of the call can be accessed on Emergent’s website emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
